American Portfolios Advisors’s TherapeuticsMD TXMD Stock Holding History

American Portfolios Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$133	Hold	20	–	–	﹤0.01%	3475
2022 Q2	$199	Sell	20 -268	-93%	-$2.56K	﹤0.01%	3464
2022 Q1	$5.47K	Sell	288 -20	-6%	-$315	﹤0.01%	2913
2021 Q4	$5.47K	Hold	308	–	–	﹤0.01%	2860
2021 Q3	$11.4K	Hold	308	–	–	﹤0.01%	2516
2021 Q2	$18.3K	Buy	308 +20	+7%	+$1.21K	﹤0.01%	2264
2021 Q1	$19.3K	Hold	288	–	–	﹤0.01%	2093
2020 Q4	$17.4K	Hold	288	–	–	﹤0.01%	1873
2020 Q3	$22.8K	Hold	288	–	–	﹤0.01%	1646
2020 Q2	$18K	Hold	288	–	–	﹤0.01%	1684
2020 Q1	$15.3K	Hold	288	–	–	﹤0.01%	1639
2019 Q4	$34.8K	Hold	288	–	–	﹤0.01%	1495
2019 Q3	$52.3K	Hold	288	–	–	﹤0.01%	1259
2019 Q2	$37.4K	Hold	288	–	–	﹤0.01%	1396
2019 Q1	$70.1K	Hold	288	–	–	0.01%	1045
2018 Q4	$54.9K	Hold	288	–	–	0.01%	972
2018 Q3	$94.5K	Hold	288	–	–	0.01%	852
2018 Q2	$89.9K	Buy	288 +128	+80%	+$39.1K	0.01%	846
2018 Q1	$39K	Buy	160 +140	+700%	+$39.3K	0.01%	1128
2017 Q4	$6.04K	Buy	+20	New	+$5.57K	﹤0.01%	1762

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

American Portfolios Advisors's TXMD Position: Q3 2022 in Review

American Portfolios Advisors held its TherapeuticsMD (TXMD) position steady in Q3 2022 at 20 shares worth $133. The position accounts for ﹤0.01% of the portfolio, ranked #3475.

American Portfolios Advisors first reported a position in TXMD in Q4 2017 and has held it in 20 quarters since. The position peaked at $94.5K in Q3 2018. 43 funds tracked by Wall St. Rank hold TXMD as of Q3 2022.

American Portfolios Advisors held 20 shares of TherapeuticsMD worth $133 as of Q3 2022.
American Portfolios Advisors left its TherapeuticsMD share count unchanged in Q3 2022.
TherapeuticsMD made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #3475 holding.
American Portfolios Advisors first reported a position in TherapeuticsMD in Q4 2017 and has held it in 20 quarters since.
American Portfolios Advisors's TherapeuticsMD position peaked at $94.5K in Q3 2018.
43 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.